Abstract
Acute Kidney Injury (AKI) remarkblely affect public health and need higher healthcare costs, which is life-threatening and characterized of acute decline with function. Arachidonic Acid (AA), the precursor for synthesis of various biologically active molecules and be involved in regulation of homeostasis and metabolism. Recent studies have shown that the AA cytochrome P450 (CYP450) pathway contribute to the development of AKI by EETs (the product of catalyzing epoxidation reactions), 20-HETE (the product of omega-hydroxylation reactions) and maybe potent key for the prevention and treatment of AKI. This review summarizes recent advances in AA metabolites in AKI.
Highlights
Acute kidney injury (AKI) is a common clinical syndrome that results in the accumulation of serum creatinine and urea nitrogen, mostly caused by Ischemia/Reperfusion (I/R), and its morbidity and mortality have increased within the last years [1,2,3]
Recent studies have shown that the Arachidonic Acid (AA) cytochrome P450 (CYP450) pathway contribute to the development of Acute Kidney Injury (AKI) by Epoxyeicosatrienoic Acids (EETs), 20-Hydroxeicosatetraenoic Acid (20-HETE) and maybe potent key for the prevention and treatment of AKI
Recent preclinical studies suggest that Arachidonic Acid (AA) metabolites generated by Cytochrome P450 (CYP) enzymes play an important role in the development of I/R-induced organ injury, expecially the heart and brain [4,5]
Summary
Acute kidney injury (AKI) is a common clinical syndrome that results in the accumulation of serum creatinine and urea nitrogen, mostly caused by Ischemia/Reperfusion (I/R), and its morbidity and mortality have increased within the last years [1,2,3]. Recent preclinical studies suggest that Arachidonic Acid (AA) metabolites generated by Cytochrome P450 (CYP) enzymes play an important role in the development of I/R-induced organ injury, expecially the heart and brain [4,5]. This review provide promising target for treatment with AKI by investigating the role of AA derivatives
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
